Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of $2.94, $2.87 better than the analyst estimate of $0.07. Revenue for the quarter came in at $150.48 million versus the consensus estimate of $10.04 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.